Department of Emergency, Xinhua Hospital of Shanghai Jiaotong University, NO 1665, Kongjiang Road, Shanghai 200092, PR China.
Crit Care. 2011;15(1):R42. doi: 10.1186/cc10004. Epub 2011 Jan 28.
The performance of N-terminal pro-brain natriuretic peptide (NT-proBNP) and C-reactive protein (CRP) to predict clinical outcomes in ICU patients is unimpressive. We aimed to assess the prognostic value of NT-proBNP, CRP or the combination of both in unselected medical ICU patients.
A total of 576 consecutive patients were screened for eligibility and followed up during the ICU stay. We collected each patient's baseline characteristics including the Acute Physiology and Chronic Health Evaluation II (APACHE-II) score, NT-proBNP and CRP levels. The primary outcome was ICU mortality. Potential predictors were analyzed for possible association with outcomes. We also evaluated the ability of NT-proBNP and CRP additive to APACHE-II score to predict ICU mortality by calculation of C-index, net reclassification improvement (NRI) and integrated discrimination improvement (IDI) indices.
Multiple regression revealed that CRP, NT-proBNP, APACHE-II score and fasting plasma glucose independently predicted ICU mortality (all P < 0.01). The C-index with respect to prediction of ICU mortality of APACHE II score (0.82 ± 0.02; P < 0.01) was greater than that of NT-proBNP (0.71 ± 0.03; P < 0.01) or CRP (0.65 ± 0.03; P < 0.01) (all P < 0.01). As compared with APACHE-II score (0.82 ± 0.02; P < 0.01), combination of CRP (0.83 ± 0.02; P < 0.01) or NT-proBNP (0.83 ± 0.02; P < 0.01) or both (0.84 ± 0.02; P < 0.01) with APACHE-II score did not significantly increase C-index for predicting ICU mortality (all P > 0.05). However, addition of NT-proBNP to APACHE-II score gave IDI of 6.6% (P = 0.003) and NRI of 16.6% (P = 0.007), addition of CRP to APACHE-II score provided IDI of 5.6% (P = 0.026) and NRI of 12.1% (P = 0.023), and addition of both markers to APACHE-II score yielded IDI of 7.5% (P = 0.002) and NRI of 17.9% (P = 0.002). In the cardiac subgroup (N = 213), NT-proBNP but not CRP independently predicted ICU mortality and addition of NT-proBNP to APACHE-II score obviously increased predictive ability (IDI = 10.2%, P = 0.018; NRI = 18.5%, P = 0.028). In the non-cardiac group (N = 363), CRP rather than NT-proBNP was an independent predictor of ICU mortality.
In unselected medical ICU patients, NT-proBNP and CRP can serve as independent predictors of ICU mortality and addition of NT-proBNP or CRP or both to APACHE-II score significantly improves the ability to predict ICU mortality. NT-proBNP appears to be useful for predicting ICU outcomes in cardiac patients.
N 端脑利钠肽前体(NT-proBNP)和 C 反应蛋白(CRP)在预测 ICU 患者临床结局方面的表现并不理想。我们旨在评估 NT-proBNP、CRP 或两者联合在未选择的 ICU 患者中的预后价值。
对 576 例连续患者进行了筛选,以确定其是否符合入选标准,并在 ICU 期间对其进行了随访。我们收集了每位患者的基线特征,包括急性生理学和慢性健康评估 II(APACHE-II)评分、NT-proBNP 和 CRP 水平。主要结局是 ICU 死亡率。分析潜在预测因素与结局的可能相关性。我们还通过计算 C 指数、净重新分类改善(NRI)和综合判别改善(IDI)指数,评估 NT-proBNP 和 CRP 对 APACHE-II 评分预测 ICU 死亡率的能力的加和。
多元回归显示 CRP、NT-proBNP、APACHE-II 评分和空腹血糖均独立预测 ICU 死亡率(均 P < 0.01)。APACHE-II 评分预测 ICU 死亡率的 C 指数(0.82 ± 0.02;P < 0.01)大于 NT-proBNP(0.71 ± 0.03;P < 0.01)或 CRP(0.65 ± 0.03;P < 0.01)(均 P < 0.01)。与 APACHE-II 评分(0.82 ± 0.02;P < 0.01)相比,CRP(0.83 ± 0.02;P < 0.01)或 NT-proBNP(0.83 ± 0.02;P < 0.01)或两者联合(0.84 ± 0.02;P < 0.01)与 APACHE-II 评分联合并不能显著提高 ICU 死亡率的 C 指数(均 P > 0.05)。然而,将 NT-proBNP 加至 APACHE-II 评分后,IDI 增加了 6.6%(P = 0.003),NRI 增加了 16.6%(P = 0.007);将 CRP 加至 APACHE-II 评分后,IDI 增加了 5.6%(P = 0.026),NRI 增加了 12.1%(P = 0.023);将两者联合加至 APACHE-II 评分后,IDI 增加了 7.5%(P = 0.002),NRI 增加了 17.9%(P = 0.002)。在心脏亚组(N = 213)中,NT-proBNP 而非 CRP 独立预测 ICU 死亡率,且将 NT-proBNP 加至 APACHE-II 评分可明显提高预测能力(IDI = 10.2%,P = 0.018;NRI = 18.5%,P = 0.028)。在非心脏组(N = 363)中,CRP 是 ICU 死亡率的独立预测因子,而非 NT-proBNP。
在未选择的 ICU 患者中,NT-proBNP 和 CRP 可作为 ICU 死亡率的独立预测因子,将 NT-proBNP 或 CRP 或两者联合加至 APACHE-II 评分可显著提高预测 ICU 死亡率的能力。NT-proBNP 似乎对预测心脏患者的 ICU 结局有用。